FK506、CsA致移植后糖尿病机制的异同及应对策略

Pathogenesis and managementof FK506- and CsA-induced post-transplant diabetes mellitus:Similarities and differences

他克莫司(tacrolimus,FK506)和环孢素(cyclosporine,CsA)均为临床常用的免疫抑制剂,二者均属于钙调神经磷酸酶抑制剂(calcineurin inhibitor,CNI).FK506抗排斥效果优异,虽然二者药理机制相似,但FK506较CsA更易导致移植术后糖尿病.本文分析比较二者致糖尿病机制异同与FK506、CsA引起移植术后糖尿病的应对策略.

Tacrolimus （FK506） and cyclosporine （CsA） are clinically commonly used immunosuppressive agents, and both of them belong to calcineu- rin inhibitors. FK506 is more excellent in anti- rejection therapy. They are similar in pharma- cological mechanism, but FK506 is more likely to induce post-transplant diabetes mellitus than CsA. This paper analyzes and compares the sim- ilarities and differences in the pathogenesis and management between FK506- and CsA-induced post-transplant diabetes mellitus.